Roche Doubles Down on Jnana’s RAPID Platform in $2B Deal

(November 15, 2022) | By Alex Keown.

It’s been a lucrative Tuesday for Jnana Therapeutics after it forged a second small molecule discovery and development collaboration and licensing agreement with Roche valued at up to $2 billion.

The company also raised $107 million in a Series C financing round.

Jnana will leverage its RAPID chemoproteomics platform to discover novel small molecule drugs aimed at cancer tumors and immune-mediated and neurological diseases. The company announced that each indication is considered a disease with high unmet needs.